HLA-A*01 is associated with late onset of Alzheimer's disease in Italian patients

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 4, 2009, Pages 991-999

  Guerini, F R ^a   Tinelli, C ^b   Calabrese, E ^a   Agliardi, C ^a   Zanzottera, M ^a   De Silvestri, A ^b   Franceschi, M ^c   Grimaldi, L M E ^d   Nemni, R ^a,e   Clerici, Mario ^a,e  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c IRCCS MULTIMEDICA   (Italy)

^d Fondazione Istituto San Raffaele G Giglio   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

Alzheimer's disease; APOE; HLA; Immunology; Late onset

Indexed keywords

APOLIPOPROTEIN E; HLA A ANTIGEN; APOLIPOPROTEIN E4;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ONSET AGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SEX RATIO; STATISTICAL SIGNIFICANCE; CASE CONTROL STUDY; ETHNOLOGY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; ITALY; MIDDLE AGED; PHENOTYPE; RISK ASSESSMENT; SEX DIFFERENCE; STATISTICAL MODEL;

AGE OF ONSET; AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HLA-A ANTIGENS; HUMANS; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS;

EID: 76349089314     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200414     Document Type: Article

References (34)

1. Kehoe P, Wavrant-De Vrieze F, Crook R, et al. A full genome scan for late onset Alzheimer's disease. Hum Mol Genet 1999; 8:237-45.
2. Lleó A, Blesa R, Queralt R, et al. Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain. Arch Neurol 2002; 59:1759-63.
3. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261:921-3.
4. McGeer PL, Rogers J, McGeer EG. Inflammation, anti-inflammatory agents and Alzheimer disease: the last 12 years. J Alzheimers Dis 2006; 9:271-6.
5. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43:1609-11.
6. Hauss-Wegrzyniak B, Willard LB, Del Soldato P, Pepeu G, Wenk GL. Peripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS. Brain Res 1999; 815:36-43.
7. Zandi PP, Breitner JC. Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence. Neurobiol Aging 2001; 22:811-7.
8. Dobson CB, Wozniak MA, Itzhaki RF. Do infectious agents play a role in dementia? Trends Microbiol 2003; 11:312-7.
9. Diepstra A, Niens M, Vellenga E, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus- negative Hodgkin's lymphoma. Lancet 2005; 365:2216-24.
10. Niens M, Jarrett RF, Hepkema B, et al. HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma. Blood 2007; 110:3310-5.
11. Listi F, Candore G, Balistreri CR, et al. Association between the HLA-A2 allele and Alzheimer disease. Rejuvenation Res 2006; 9:99-101.
12. Payami H, Schellenberg GD, Zareparsi S, et al. Evidence for association of HLA-A2 allele with onset age of Alzheimer's disease. Neurology 1997; 49:512-8.
13. Ballerini C, Nacmias B, Rombolà G, Marcon G, Massacesi L, Sorbi S. HLA A2 allele is associated with age at onset of Alzheimer's disease. Ann Neurol 1999; 45:397-400.
14. Harris JM, Cumming AM, Craddock N, St Clair D, Lendon CL. Human leucocyte antigen-A2 increases risk of Alzheimer's disease but does not affect age of onset in a Scottish population. Neurosci Lett 2000; 294:37-40.
15. Zareparsi S, James DM, Kaye JA, Bird TD, Schellenberg GD, Payami H. HLA-A2 homozygosity but not heterozygosity is associated with Alzheimer disease. Neurology 2002; 58:973-5.
16. Araria-Goumidi L, Lambert JC, Cottel D, Amouyel P, Chartier-Harlin MC. No association of the HLA-A2 allele with Alzheimer's disease. Neurosci Lett 2002; 335:75-8.
17. Nourhashémi F, Gillette-Guyonnet S, Fort M, Andrieu S, Abbal M, Albarede JL, Vellas B. Association between the A2 allele of the HLA system and age at onset of Alzheimer's disease. Presse Med 2003; 32:158-61.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's Disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Service Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-44.
19. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state" A practical method for grading the cognitive state of patients for the clinicians. J Psychiat Res 1975; 12:189-98.
20. Olerup O, Zitterquist H. HLA -DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39:225-35.
21. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31:545-8.
22. Awadzi KD, Classen S, Hall A, Duncan RP, Garvan CW Predictors of injury among younger and older adults in fatal motor vehicle crashes. Accid Anal Prev 2008; 40:1804-10.
23. Guerini FR, Calabrese E, Agliardi C, et al. Association study of the HLA-A2 allele in Italian Alzheimer disease patients. Neurobiol Aging 2008; doi:10.1016/j.neurobiolaging.2008.02.001
24. Candore G, Balistreri CR, Colonna-Romano G, Lio D, Caruso C. Major histocompatibility complex and sporadic Alzheimer's disease: a critical reappraisal. Exp Gerontol 2004; 39:645-52.
25. Middleton D, Mawhinney H, Curran MD, et al. Frequency of HLA-A and B alleles in early and late-onset Alzheimer's disease. Neurosci Lett 1999; 26: 140-2.
26. Doxiadis IN, de Lange P, de Vries E, Persijn GG, Claas FHJ. Protective and susceptible HLA polymorphisms in IgA nephropathy patients with end-stage renal failure. Tissue Antigens 2001; 57: 344-7.
27. Peru H, Soylemezoglu O, Gonen S, Cetinyurek A, Bakkaloolu SA, Buyan N, Hasanoglu E. HLA class 1 associations in Henoch Schonlein purpura: increased and decreased frequencies. Clin Rheumatol 2008; 27:5-10.
28. Vogelsang H, Panzer S, Mayr WR, Granditsch G, Fischer GF. Distribution of HLA Class I Alleles Differs in Celiac Disease Patients According to Age of Onset. Dig Dis Sci 2003; 48:611-4.
29. Lio D, Candore G, Colombo A, et al. A genetically determined high setting of TNF-alpha influences immunologic parameters of HLA-B8,DR3 positive subjects: implications for autoimmunity. Hum Immunol 2001; 62:705-13.
30. Fensterle J, Trefzer U, Berger T, Andersen MH, Ugurel S, Becker JC. HLA-B8 association with late-stage melanoma-an immunological lesson? BMC Med 2006; 13:4-5.
31. Candore G, Campagna AM, Cuppari I, Di Carlo D, Mineo C, Caruso C. Genetic control of immune response in carriers of the 8.1 ancestral haplotype: correlation with levels of IgG subclasses: its relevance in the pathogenesis of autoimmune diseases. Ann N Y Acad Sci 2007; 1110:151-8.
32. Lambert JC, Amouyel P. Genetic heterogeneity of Alzheimer's disease: complexity and advances. Psychoneuroendocrinology 2007; 1(S):62-70.
33. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90:8098-102.
34. Waring SC, Rosenberg RN. Genome-wide association studies in Alzheimer disease. Arch Neurol 2008; 65:329-34.